Spotlight On... Recent controversy hasn't hurt brand value for Pfizer, Valeant: report; Doctors Without Borders backs ViiV patent opposition in India; Shire deputy chairman set to step down in April; and more...

Plenty of pharma companies saw their brand values drop between 2015 and 2016 as weaker demand for their products wreaked havoc. But not Pfizer ($PFE) and Valeant ($VRX), both of which posted brand valuation increases greater than 30% in this year's Brand Finance ranking. More from FiercePharmaMarketing

@FiercePharma: Zika update: Vaccine race swells, PaxVax CEO on how to stop 'chasing epidemics.' Article | Follow @FiercePharma

@CarlyHFierce: ICYMI: Actelion exceeds profit estimates as Opsumit, Uptravi make up for aged Tracleer. Report | Follow @CarlyHFierce

> Doctors Without Borders is supporting opposition to GlaxoSmithKline ($GSK) and Pfizer ($PFE) joint venture ViiV Healthcare's quest to nab patents for a pair of its HIV drugs in India. Release

> Shire's ($SHPG) deputy chairman and senior independent director David Kappler will step down, effective April 28; he'll be replaced in the senior independent director spot by Bill Burns. Report

> India's Cipla said its quarterly profit missed analysts' expectations thanks to a one-off charge related to changes in the way it distributes drugs in India. Report

> Novartis ($NVS) is taking aim at proposed changes to the U.K. Cancer Drugs Fund, which pays for treatments not cleared as cost-effective by government watchdogs. Report

> Merck ($MRK) has filed for FDA approval for its dust mite allergy treatment. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: BTG, Philips roll out first cancer embolic bead visible via real-time imaging. Article | Follow @FierceMedDev

@EmilyWFierce: Hikma slashes $535M from offer price for Boehringer's U.S. generics biz. FiercePharma story | Follow @EmilyWFierce

> Smith & Nephew to sell OrthAlign precision alignment tech alongside its artificial knees. Story

> As Zika fears spread, Cerus nabs American Red Cross partnership for blood pathogen reduction. Article

Biotech News

@FierceBiotech: Oxford team fingers an inflammatory protein as a trigger for cancer. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: AbbVie taps Synlogic to take a microbiomic approach to IBD. News | Follow @JohnCFierce

@DamianFierce: oh to be a fly on the wall as WSJ editors discussed how best to word this paragraph. More/Article (sub. req.) | Follow @DamianFierce

> Astellas finally wraps up its $379M deal for Ocata. Story

> Pending Allergan merger stirs layoff fears among Pfizer scientists. Item

> Celgene, Google ante up for Armo's next-gen IL-10/PD-1 immuno-oncology combos. Article

Pharma Marketing News

> Novartis bolsters its home-turf advantage in psoriasis with Cosentyx DTC push. Story

> Big Pharma's new PCSK9, heart failure meds stuck in the slow lane. What gives? More

> Pfizer and Valeant jump in annual brand analysis, but most other pharmas drop. Report

> FDA pushes CTI to pull app for myelofibrosis med after trial deaths. Item

> PhRMA hopes to polish pharma's tarnished rep with patient-focused ad campaign. Article

Biotech Research News

> Oxford team fingers an inflammatory protein as a trigger for cancer. Report

> Study: LDL, omega-3 nano-strategy eliminates liver cancer cells in rats. More

> Sequencing deer tick genome may help stop Lyme disease one day. Item

> CRUK scientists ID a key player behind the spread of breast cancer cells. Story

> NIH researchers find genomic signature common in 5 types of cancer. Article

Vaccines News

> As corporate restructuring looms, Sanofi's vaccines deliver in 2015. More

> Zika update: Vaccine race swells, PaxVax CEO on how to stop 'chasing epidemics.' Report

> GlaxoSmithKline signs two new vaccine R&D partnerships. Story

> Bavarian Nordic launches MRSA vaccine effort with partner Evaxion. Item

> GSK's vax revenues jump in 2015 while profit, margin slip. Article

And Finally... The National Institute for Health and Care Excellence (NICE) in England put out new guidelines for treatment of multiple myeloma. Report